Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. (Q43037854)

12 November 2017

title

Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. (English)

1 reference

12 November 2017

1 reference

F J Castro

1

1 reference

12 November 2017

J I Esteban

2

1 reference

12 November 2017

A Juárez

3

1 reference

12 November 2017

S Sauleda

4

1 reference

12 November 2017

L Viladomiu

5

1 reference

12 November 2017

M Martell

6

1 reference

12 November 2017

F Moreno

7

1 reference

12 November 2017

H Allende

8

1 reference

12 November 2017

R Esteban

9

1 reference

12 November 2017

J Guardia

10

1 reference

12 November 2017

publication date

1 May 2002

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

9

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

202-207

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Evaluation of hepatitis C virus RNA RT/PCR qualitative and quantitative second generation assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Hepatitis C virus resistance to antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00348.X

10.1046/J.1365-2893.2002.00348.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference